Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) ALUR Phase III Trial: Alectinib vs. Chemotherapy in ALK-Positive NSCLC After Crizotinib Jun 30, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial Jun 23, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Pembrolizumab Vs. Chemotherapy as First-Line Therapy in Individuals With NSCLC Jun 23, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Durvalumab after Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC Jun 23, 2023
Lung Cancer,SCLC (Small Cell Lung Cancer) Patient-Reported AEs in ES-SCLC Treated With Durvalumab Plus EP or EP Alone Jun 09, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Pooled Analysis Shows Durable Survival With First-Line Nivolumab Plus Ipilimumab in aNSCLC Jun 09, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) AE Burden of Nivolumab-Based IO Therapy in 1L Advanced NSCLC With/Without Chemo Jun 09, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Lorlatinib Shows Superior Efficacy and Safety Compared to Crizotinib in Advanced ALK-Positive NSCLC Jun 09, 2023
